IMCRライブシグナル | Getagraph.comで利益を最大化

買う 107746 min ago

@ $71.91

発行日: 15 2月 2024 @ 05:47

リターン: -17.57%

前回のシグナル: 2月 14 - 23:30

前回のシグナル: 売る

リターン: -2.49 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:33):

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases...

Stats
本日の出来高	198 672
平均出来高	512 688
時価総額	2.95B
EPS	$0 ( 2024-02-28 )
次の収益日	( $-0.320 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-41.74
ATR14	$0.103 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	St Leger Tina Amber	Sell	4 375	Employee Share Option (Right to Buy)
2024-04-01	St Leger Tina Amber	Buy	4 375	Ordinary Shares
2024-04-01	St Leger Tina Amber	Sell	4 375	Ordinary Shares
2024-02-28	Berman David M	Sell	36 509	Employee Share Option (Right to Buy)
2024-02-28	Berman David M	Buy	36 509	Ordinary Shares

INSIDER POWER
-75.94
Last 63 transactions
Buy: 607 651 \| Sell: 4 752 433

ボリューム相関

長: 0.08 (neutral)

短: -0.14 (neutral)

Signal:(39.533) Neutral

Immunocore Holdings plc 相関

10 最も正の相関
AMRB	0.859
LWAC	0.837
MMAC	0.835

10 最も負の相関
SVAC	-0.83
TLGT	-0.821

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Immunocore Holdings plc 相関 - 通貨/商品

-0.88
( strong negative )

-0.74
( moderate negative )

0.00
( neutral )

-0.21
( neutral )

-0.28
( neutral )

0.21
( neutral )

Immunocore Holdings plc 財務諸表

Annual	2023
収益:	$249.43M
総利益:	$248.39M (99.58 %)
EPS:	$-0.00110

FY	2023
収益:	$249.43M
総利益:	$248.39M (99.58 %)
EPS:	$-0.00110

FY	2022
収益:	$143.74M
総利益:	$143.28M (99.68 %)
EPS:	$-0.900

FY	2021
収益:	$26.52M
総利益:	$0.00 (0.00 %)
EPS:	$-3.10

Financial Reports:

No articles found.

Immunocore Holdings plc

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.